Management of anemia in children receiving chronic dialysis

Meredith A. Atkinson; Bradley A. Warady

doi:10.1007/978-3-030-66861-7_32

Management of anemia in children receiving chronic dialysis

Meredith A. Atkinson, Bradley A. Warady

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

In 1839, the Scottish physician Robert Christison noted that anemia was a common feature of kidney disease, writing that "no other natural disease came as close to hemorrhage for impoverishing the red particles of the blood" [1, 2]. Anemia is a comorbidity affecting nearly all children treated with chronic dialysis, and its management remains challenging for clinicians. The emergence of recombinant human erythropoietin (rHuEPO) more than 30 years ago revolutionized anemia management in the dialysis population and eliminated dependence on red blood cell transfusions for most patients. Increased understanding of the molecular regulation of EPO production and iron metabolism has opened the door for the development of novel erythropoiesis-stimulating agents (ESA) and renal anemia therapies.

Original language	English (US)
Title of host publication	Pediatric Dialysis
Subtitle of host publication	Third Edition
Publisher	Springer International Publishing
Pages	609-631
Number of pages	23
ISBN (Electronic)	9783030668617
ISBN (Print)	9783030668600
DOIs	https://doi.org/10.1007/978-3-030-66861-7_32
State	Published - May 1 2021

Keywords

Anemia
Dialysis
Erythropoietin
ESAs
Hemoglobin
Iron

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-030-66861-7_32

Cite this

@inbook{29256c7c2a4f45d8950b5ce37830e0f8,

title = "Management of anemia in children receiving chronic dialysis",

abstract = "In 1839, the Scottish physician Robert Christison noted that anemia was a common feature of kidney disease, writing that {"}no other natural disease came as close to hemorrhage for impoverishing the red particles of the blood{"} [1, 2]. Anemia is a comorbidity affecting nearly all children treated with chronic dialysis, and its management remains challenging for clinicians. The emergence of recombinant human erythropoietin (rHuEPO) more than 30 years ago revolutionized anemia management in the dialysis population and eliminated dependence on red blood cell transfusions for most patients. Increased understanding of the molecular regulation of EPO production and iron metabolism has opened the door for the development of novel erythropoiesis-stimulating agents (ESA) and renal anemia therapies.",

keywords = "Anemia, Dialysis, Erythropoietin, ESAs, Hemoglobin, Iron",

author = "Atkinson, {Meredith A.} and Warady, {Bradley A.}",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2021.",

year = "2021",

month = may,

day = "1",

doi = "10.1007/978-3-030-66861-7_32",

language = "English (US)",

isbn = "9783030668600",

pages = "609--631",

booktitle = "Pediatric Dialysis",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Management of anemia in children receiving chronic dialysis

AU - Atkinson, Meredith A.

AU - Warady, Bradley A.

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2021.

PY - 2021/5/1

Y1 - 2021/5/1

N2 - In 1839, the Scottish physician Robert Christison noted that anemia was a common feature of kidney disease, writing that "no other natural disease came as close to hemorrhage for impoverishing the red particles of the blood" [1, 2]. Anemia is a comorbidity affecting nearly all children treated with chronic dialysis, and its management remains challenging for clinicians. The emergence of recombinant human erythropoietin (rHuEPO) more than 30 years ago revolutionized anemia management in the dialysis population and eliminated dependence on red blood cell transfusions for most patients. Increased understanding of the molecular regulation of EPO production and iron metabolism has opened the door for the development of novel erythropoiesis-stimulating agents (ESA) and renal anemia therapies.

AB - In 1839, the Scottish physician Robert Christison noted that anemia was a common feature of kidney disease, writing that "no other natural disease came as close to hemorrhage for impoverishing the red particles of the blood" [1, 2]. Anemia is a comorbidity affecting nearly all children treated with chronic dialysis, and its management remains challenging for clinicians. The emergence of recombinant human erythropoietin (rHuEPO) more than 30 years ago revolutionized anemia management in the dialysis population and eliminated dependence on red blood cell transfusions for most patients. Increased understanding of the molecular regulation of EPO production and iron metabolism has opened the door for the development of novel erythropoiesis-stimulating agents (ESA) and renal anemia therapies.

KW - Anemia

KW - Dialysis

KW - Erythropoietin

KW - ESAs

KW - Hemoglobin

KW - Iron

UR - http://www.scopus.com/inward/record.url?scp=85150980801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150980801&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-66861-7_32

DO - 10.1007/978-3-030-66861-7_32

M3 - Chapter

AN - SCOPUS:85150980801

SN - 9783030668600

SP - 609

EP - 631

BT - Pediatric Dialysis

PB - Springer International Publishing

ER -

Management of anemia in children receiving chronic dialysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this